<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672189</url>
  </required_header>
  <id_info>
    <org_study_id>NKI 2014-6788 / NL53182.031.15</org_study_id>
    <nct_id>NCT02672189</nct_id>
  </id_info>
  <brief_title>Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms</brief_title>
  <official_title>A Randomized Controlled Trial of Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study will evaluate systematically the efficacy and cost-effectiveness of two
      internet-based CBT/relaxation programs (one guided, the other self-managed) in reducing the
      severity of menopausal symptoms and improving copings skills with regard to hot flushes and
      night sweats as well as improving sexual functioning, improving quality of sleep, reducing
      emotional distress and improving quality of life in younger breast cancer patients who
      experience treatment-induced menopause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Breast cancer is the most common cancer among women in the Netherlands, with
      approximately 14.000 new cases reported in 2011 (1). Nearly 30% of all women with breast
      cancer are premenopausal at the time of diagnosis (2). Ovarian damage is a major long-term
      sequela of chemotherapy in premenopausal women (3,4). Ovarian failure induced by chemotherapy
      and/or endocrine treatment leads to an earlier onset of menopause, with age and duration of
      treatment being its strongest predictors (5).

      Premature menopause is a major concern of younger women undergoing (adjuvant/preventive)
      therapy for cancer (6). Primary menopausal symptoms include hot flushes, night sweats,
      vaginal dryness, decreased libido, dysuria and urinary incontinence. Secondary symptoms
      include insomnia due to night sweats, dyspareunia because of vaginal dryness, weight gain,
      and psychological distress (3,7,8). Previous studies have indicated that the severity of hot
      flushes is increased in women who experience transition into menopause during cancer
      treatment or after PBSO, compared to women going through natural menopause (9,10,11).

      Among menopausal symptoms, hot flushes are considered to be the most disruptive, with
      prevalence rates between 63% and 80% in breast cancer patients (7,12-15). Moreover, vasomotor
      symptoms are an important reason why some women discontinue tamoxifen treatment (16,17).
      Hormonal replacement therapy (HRT) is highly effective in alleviating vasomotor symptoms
      associated with menopause (18). However, HRT is contraindicated in women with a history of
      breast cancer (19), even after prophylactic bilateral salpingo oophorectomy (PBSO) (20).

      There is increasing evidence that behavioral interventions have a positive impact on symptoms
      in women with naturally occurring and treatment-induced menopause (21-27). A cognitive
      behavioral therapy (CBT) intervention including information about symptoms, monitoring and
      modifying precipitants, relaxation and stress management, cognitive restructuring of
      unhelpful assumptions and automatic thoughts, and encouraging helpful behavioral strategies
      has been found to be beneficial in the alleviation of menopausal symptoms in women with
      breast cancer (25,26), but compliance with face-to-face CBT programs can be problematic (26).
      A promising approach is to make this form of CBT more accessible and feasible for
      participants by having it available via the internet. Although the efficacy of CBT for this
      patient population has been demonstrated in the form of face-to-face group therapy, its
      efficacy has not been investigated when delivered via an internet platform in an individual
      setting.

      Design. For this trial patients will be recruited from several hospitals in the Netherlands
      (predominantly Amsterdam region). Participants will be randomly allocated to either the
      guided intervention group, the self-management group or the control group (N = 83 per group).
      Upon completion of the study, the patients assigned to the control group will be given the
      opportunity to undergo the internet-based cognitive behavioral therapy program.

      Women in the two intervention and control group will be asked to complete a battery of
      questionnaires prior to randomization (TO), at 10 weeks (T1) and at 6 months (T2).

      Study measures. The primary outcomes are menopausal complaints, as assessed with a menopausal
      complaints questionnaire, the Functional Assessment of Cancer Therapy - Endocrine Symptoms
      (FACT-ES), and hot flushes and night sweats as assessed by the Hot Flushes Rating Scale
      (HFRS). The secondary study outcomes are sexuality problems (the Sexual Activity
      Questionnaire (SAQ)); sleep quality (The Groningen Sleep Quality Score (GSQS)); psychological
      distress (The Hospital Anxiety and Depression Scale (HADS)) and health related quality of
      life (The Medical Outcome Study 36-Item Short Form-36 Health Survey (SF-36)).

      Patients' evaluation of the intervention program. The women in both intervention groups will
      be asked to provide their opinion of the internet-based CBT program at the 10 week evaluation
      point. All these women will be asked to complete a short questionnaire about the perceived
      efficacy of and satisfaction with the intervention program, whether they would suggest any
      changes to the program, and if they would recommend it to other women experiencing symptoms
      of premature menopause. In addition, telephone interviews (30 minutes) will be held with
      women who: (1) stated in the questionnaire that the intervention did not have the desired
      effect; and/or (2) gave the intervention a low rating (&lt;6) and/or (3) would not recommend the
      program to others.

      Cost effectiveness. The cost-effectiveness of the internet-based guided CBT versus the
      internet-based self-management CBT versus usual care will be expressed as: (1) cost per
      patient with a clinically relevant significant reduction on the HFRS and (2) cost per quality
      adjusted life year (QALY) gained.

      Sample size and statistical power calculations: In total, 248 women will be recruited into
      the study, to allow for an attrition rate of approximately 20% (i.e., women who discontinue
      participation in the study entirely, including failure to complete all follow-up
      questionnaires; those women who discontinue participation in one of the groups but complete
      the follow-up assessments will be included in the analysis). Thus, a minimum of 130 women
      will be available for the primary intention-to-treat analysis. With a total sample of 130
      women (65 per group), the study will have 80% power to detect an effect size of 0.5 with a p
      value of 0.05 (28).

      Statistical analyses: Analyses will first be performed to evaluate the comparability of the
      intervention groups (guided versus self-management) and control group at baseline in terms of
      sociodemographic and clinical characteristics. ANOVA tests or appropriate non-parametric
      statistics will be used, depending on the level of measurement. If, despite the stratified
      randomization procedures, the groups are found not to be comparable on one more background
      variables, those variables will be employed routinely as covariates in subsequent analyses.

      We will evaluate between-group differences over time in self-reported endocrine symptoms,
      sexual functioning, psychological distress, sleep quality and HRQOL. Scores for the FACT-ES,
      the HFRS, the SAQ, the HADS, the GSQS, and the SF-36 and the utility version of the SF-36,
      the SF-6D will be calculated according to published scoring algorithms.We will compare both
      intervention groups with the control group over time using multilevel procedures with
      repeated measures, using a restricted maximum likelihood (REML) solution to model specific
      contrasts between groups and follow-up assessment (29). Within each multilevel model the
      control group will be the reference category. Differences in mean change scores over time
      between the intervention groups and the control group will be accompanied by effect sizes
      (ES). As indicated previously, the FACT-ES and the HFRS will be used as the primary study
      endpoints, and the remaining measures will be considered as secondary endpoints. The p-value
      for overall model effects will be set at 0.05, and for specific contrasts at 0.01, lowering
      the risk of Type errors due to multiple testing.

      All analyses will be conducted on an intention-to-treat (ITT) basis. In addition,
      per-protocol (PP) analyses will be performed on patients who met criteria for minimal
      compliance with the intervention(s). Supplementary analyses will be carried out in which data
      relating to compliance with the program elements is taken into account. Specifically, we will
      determine whether the level of compliance (based on completed homework assignments and
      self-report data) is associated significantly with the changes over time in symptom relief,
      sexuality, psychological distress, sleep quality, and cost-effectiveness. In addition the
      potential mediating effect of hot flush beliefs and behaviors will be examined through
      mediator analysis.

      A cost-effectiveness analysis (CEA) will be performed using a validated health economic model
      as developed for use in the EVA-Trial (30). The analysis will consider the societal
      perspectives, the third-party payer perspective and the healthcare system perspective in
      comparing the effectiveness and costs of web-based CBT for alleviating treatment-induced
      menopausal symptoms versus waiting list control. Effectiveness data as gathered from the
      trial will be combined with the cost data from the cost-diary and hospital administration
      data.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in overall levels of menopausal symptoms</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Overall levels of menopausal symptoms are assessed by using the FACT-ES</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vasomotor symptoms</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Vasomotor symptoms are assessed with the Hot Flush Rating Scale (HFRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in overall levels of sexual functioning</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>The overall levels of sexual functioning are assessed with the Sexual Activity Questionnaire (SAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychological distress</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Psychological distress is assessed with the Hospital Anxiety and Depression Scale (HADS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sleep quality</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Sleep quality is assessed with the Groningen Sleep Quality Scale (GSQS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hot flush frequency</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Hot flush frequency is assessed with the frequency subscale of the Hot Flush Rating Scale (HFRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life</measure>
    <time_frame>Baseline (T0); 10 weeks post baseline (T1) and 6 months post baseline (T2)</time_frame>
    <description>Health related quality of life is assessed with the SF-36 questionnaire</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">265</enrollment>
  <condition>Climacteric Symptoms</condition>
  <condition>Breast Cancer Survivors</condition>
  <arm_group>
    <arm_group_label>Waiting list control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVA-Online guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).
Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVA-Online self-management group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>EVA-Online</intervention_name>
    <description>Internet-based cognitive behavioral therapy</description>
    <arm_group_label>EVA-Online guided group</arm_group_label>
    <arm_group_label>EVA-Online self-management group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Age limit: stated age concerns age at time of diagnosis.

        Inclusion Criteria:

          -  Female

          -  Diagnosis of histologically confirmed primary breast cancer

          -  50 years or younger at time of diagnosis

          -  Premenopausal at time of diagnosis

          -  Treatment induced menopause due to at least one of the following treatment regimens:
             1) chemotherapy (&lt; 5 years &gt; 4 months); 2) hormonal therapy (&lt;5 years; may currently
             receive hormonal treatment); oophorectomy (&lt; 5 years &gt; 4 months)

          -  Disease free at time of study entry

          -  Presence of menopausal symptoms

        Exclusion Criteria:

          -  Lacks basic proficiency in Dutch

          -  No access to the internet

          -  Serious cognitive or psychiatric problems

          -  Participation in concurrent studies and/or therapy programs to alleviate menopausal
             symptoms
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil K. Aaronson, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hester S.A. Oldenburg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Van Beurden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Cijfers over kanker, Nederlandse Kankerregistratie,beheerd door IKNL Â© januari 2014, 2014</citation>
  </reference>
  <reference>
    <citation>Society. AC: Cancer Facts Figures - 2000. Atlanta, GA, 2003</citation>
  </reference>
  <reference>
    <citation>Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718-29. Review.</citation>
    <PMID>8622093</PMID>
  </reference>
  <reference>
    <citation>Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001 Jun 28;344(26):1997-2008. Review.</citation>
    <PMID>11430330</PMID>
  </reference>
  <reference>
    <citation>Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999 Aug;17(8):2365-70.</citation>
    <PMID>10561298</PMID>
  </reference>
  <reference>
    <citation>Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psychooncology. 2004 May;13(5):295-308.</citation>
    <PMID>15133771</PMID>
  </reference>
  <reference>
    <citation>Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol. 1995 Nov;13(11):2737-44.</citation>
    <PMID>7595732</PMID>
  </reference>
  <reference>
    <citation>Biglia N, Cozzarella M, Cacciari F, Ponzone R, Roagna R, Maggiorotto F, Sismondi P. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003 May 30;45(1):29-38.</citation>
    <PMID>12753941</PMID>
  </reference>
  <reference>
    <citation>Rosenberg SM, Partridge AH. Premature menopause in young breast cancer: effects on quality of life and treatment interventions. J Thorac Dis. 2013 Jun;5 Suppl 1:S55-61. doi: 10.3978/j.issn.2072-1439.2013.06.20.</citation>
    <PMID>23819028</PMID>
  </reference>
  <reference>
    <citation>Crandall C, Petersen L, Ganz PA, Greendale GA. Association of breast cancer and its therapy with menopause-related symptoms. Menopause. 2004 Sep-Oct;11(5):519-30.</citation>
    <PMID>15356404</PMID>
  </reference>
  <reference>
    <citation>Benshushan A, Rojansky N, Chaviv M, Arbel-Alon S, Benmeir A, Imbar T, Brzezinski A. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric. 2009 Oct;12(5):404-9. doi: 10.1080/13697130902780846.</citation>
    <PMID>19479488</PMID>
  </reference>
  <reference>
    <citation>Bloom JR, Stewart SL, Chang S, Banks PJ. Then and now: quality of life of young breast cancer survivors. Psychooncology. 2004 Mar;13(3):147-60.</citation>
    <PMID>15022150</PMID>
  </reference>
  <reference>
    <citation>Carpenter JS, Andrykowski MA, Cordova M, Cunningham L, Studts J, McGrath P, Kenady D, Sloan D, Munn R. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer. 1998 May 1;82(9):1682-91.</citation>
    <PMID>9576289</PMID>
  </reference>
  <reference>
    <citation>Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum. 1999 Sep;26(8):1311-7.</citation>
    <PMID>10497770</PMID>
  </reference>
  <reference>
    <citation>Hunter MS, Grunfeld EA, Mittal S, Sikka P, Ramirez AJ, Fentiman I, Hamed H. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology. 2004 Nov;13(11):769-78.</citation>
    <PMID>15386641</PMID>
  </reference>
  <reference>
    <citation>Owusu C, Buist DS, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008 Feb 1;26(4):549-55. Epub 2007 Dec 10.</citation>
    <PMID>18071188</PMID>
  </reference>
  <reference>
    <citation>Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006 Sep;99(2):215-20. Epub 2006 Mar 16.</citation>
    <PMID>16541307</PMID>
  </reference>
  <reference>
    <citation>MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2001;(1):CD002978. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD002978.</citation>
    <PMID>11279791</PMID>
  </reference>
  <reference>
    <citation>Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004 Feb 7;363(9407):453-5.</citation>
    <PMID>14962527</PMID>
  </reference>
  <reference>
    <citation>Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond). 2012 Sep;8(5):543-55. doi: 10.2217/whe.12.41.</citation>
    <PMID>22934728</PMID>
  </reference>
  <reference>
    <citation>Hunter MS: Cognitive behavioural interventions for premenstrual and menopausal problems. J Reprod Infant Psychol:183-193, 2003</citation>
  </reference>
  <reference>
    <citation>Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol. 1996 Dec;17(4):202-7.</citation>
    <PMID>8997686</PMID>
  </reference>
  <reference>
    <citation>Lindh-Astrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas. 2004 Jun 15;48(2):97-105.</citation>
    <PMID>15172083</PMID>
  </reference>
  <reference>
    <citation>Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012 Jul;19(7):749-59. doi: 10.1097/gme.0b013e31823fe835.</citation>
    <PMID>22336748</PMID>
  </reference>
  <reference>
    <citation>Mann E, Smith MJ, Hellier J, Balabanovic JA, Hamed H, Grunfeld EA, Hunter MS. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012 Mar;13(3):309-18. doi: 10.1016/S1470-2045(11)70364-3. Epub 2012 Feb 15.</citation>
    <PMID>22340966</PMID>
  </reference>
  <reference>
    <citation>Duijts SF, van Beurden M, Oldenburg HS, Hunter MS, Kieffer JM, Stuiver MM, Gerritsma MA, Menke-Pluymers MB, Plaisier PW, Rijna H, Lopes Cardozo AM, Timmers G, van der Meij S, van der Veen H, Bijker N, de Widt-Levert LM, Geenen MM, Heuff G, van Dulken EJ, Boven E, Aaronson NK. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol. 2012 Nov 20;30(33):4124-33. doi: 10.1200/JCO.2012.41.8525. Epub 2012 Oct 8.</citation>
    <PMID>23045575</PMID>
  </reference>
  <reference>
    <citation>Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64.</citation>
    <PMID>10880548</PMID>
  </reference>
  <reference>
    <citation>Cohen J: Statistical power analysis for the behavioral sciences. Hillsdale, New Jersey, Lawrence Earlbaum Associates, 1988</citation>
  </reference>
  <reference>
    <citation>Diggle P, Heagerty P, Liang K, et al: Analysis of longitudinal data. New York, Oxford University Press, 2002</citation>
  </reference>
  <reference>
    <citation>Mewes JC, Steuten LM, Duijts SF, Oldenburg HS, van Beurden M, Stuiver MM, Hunter MS, Kieffer JM, van Harten WH, Aaronson NK. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. J Cancer Surviv. 2015 Mar;9(1):126-35. doi: 10.1007/s11764-014-0396-9. Epub 2014 Sep 2.</citation>
    <PMID>25179578</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Climacteric symptoms</keyword>
  <keyword>Menopause</keyword>
  <keyword>Breast Cancer Survivors</keyword>
  <keyword>Internet-based</keyword>
  <keyword>Cognitive behavioral therapy</keyword>
  <keyword>Psychosocial intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

